CIOMS Working Group VI. 2005.Management of Safety
Information from Clinical Trials.CIOMS: Geneva.
Collins GE, Clay MM, Falletta JM. 1974. A prospective
study of the epidemiology of adverse drug reactions
in paediatric hematology and oncology patients.Am.
J. Hosp. Pharm. 31 : 968–975.
Corzo D,et al.1995. The major histocompatibility
complex region marked by HSP70-1 and HSP70-2
variants is associated with clozapine-induced agra-
nulocytosis in two different ethnic groups.Blood 86 :
3835–3840.
Faich GA, Castle W, Bankowski Z, and the Council for
International Organizations of Medical Sciences
(CIOMS) ADR Working Group. 1990. International
adverse drug reporting. The CIOMS project.J. Clin.
Res. Pharmacoepidemiol. 4 : 83–90.
FDA. 1992.FDA Med Bull.22(1).
Finney DJ. 1982. The detection of adverse reactions to
therapeutic drugs.Stat. Med. 1 : 153–161.
Fletcher AP. 1991. Spontaneous adverse drug reaction
reporting vs. event monitoring: a comparison.J. R.
Soc. Med. 84 : 341–344.
Gustafson SR (ed.). 1969.The Pediatric Patient.J.F.
Lipworth: Philadelphia, PA; 112–115.
Kessler DA. 1993. Introducing MEDWatch. A new
approach to reporting medication and device adverse
effects and product problems.J. Am. Med. Assoc.
269 : 183–189.
Koch-Weser J, Sellers EM, Zacest R. 1977. The ambi-
guity of adverse drug reactions.Eur. J. Clin. Phar-
macol. 11 : 75–78.
Lasagna L. 1983. Discovering adverse drug reactions.
J. Am. Med. Assoc. 249 : 2224–2225.
Lumpkin M. 2000. CIOMS V: pragmatic approaches
to some current challenges in pharmacovigilance.
US Food and Drug Administration, 9 March;
16 May 2006 (http://www.fda.gov/cder/present/
dianice 2000/dianice2/index.htm).
Nolan L, O’Malley K. 1988. Prescribing for the elderly.
Part 1: Sensitivity of the elderly to adverse drug
reactions.J. Am. Geriat. Soc. 36 : 142–149.
Peck CC, Temple R, Collins JM. 1993. Understanding
consequences of concurrent therapies.J. Am. Med.
Assoc. 269 : 1550–1552.
Rawlins MD, Thompson JW. 1977. Pathogenesis of
adverse drug reactions. InTextbook of Adverse Drug
Reactions, Davies DM (ed.). Oxford University
Press: Oxford.
Sachs RM, Bortnichak EA. 1986. An evaluation of
spontaneous adverse drug reaction monitoring sys-
tems.Am. J. Med. 81 (Suppl. 5B): 49–55.
Second International Conference on Harmonization.
1994 Topic E2. Clinical safety data management:
definitions and standards for expedited reporting.
Step 4.
Stephenson WP. 2005. FDA Public Hearing: Reporting
of Adverse Events to Institutional Review Boards,
CIOMS VI Working Group Proposals. US Food
and Drug Administration, 21 March 2005; 16 May
2006 (http://www.fda.gov/ohrms/dockets/dockets/
05n0038/05n-0038-ts00015-02-Stephenson.pdf).
Venning GR. 1983. Identification of adverse reactions
to new drugs. II. How were 18 important adverse
reactions discovered and with what delays?Br. Med.
J. 286 : 289–292.
Wardell WM,et al.1979. Postmarketing surveillance of
new drugs. I Review of objectives and methodology.
J. Clin. Pharmacol. 19 (2–3): 85–94.
Weber JCP. 1984. Epidemiology of adverse reactions to
non-steroidal antiinflammatory drugs. InAdvances
in Inflammation Research, vol. 6, Rainsford KD,
Velo EP (eds). Raven: New York; 1–7.
Worden DE. 1995. The drive toward regulatory harmo-
nization: what is harmonization and how will it
impact the global development of new drugs?Drug
Inform. J. 29 : 1663S–1679S.REFERENCES AND RESOURCES 543